Servizio Comunitario di Informazione in materia di Ricerca e Sviluppo - CORDIS


MYCAP Sintesi della relazione

Project ID: 258984
Finanziato nell'ambito di: FP7-IDEAS-ERC
Paese: Spain

Final Report Summary - MYCAP (DEVELOPMENT OF A TECHNOLOGY TO PRODUCE MICROCAPSULES, based on the formation of drops from viscous non-Newtonian liquids sprayed through fan-jet nozzles, TO USE IN CANCER THERAPY)

An innovative drug delivery system (DDS) for tumoral cell (NSLCC) targeting and drug releasing is presented. The system consists on a bio polymeric-based high viscous gel which plays the role of a carrier which transports, due to the functionalization of its surface, a cell-membrane ligand recognizer (EGF) on one hand, working as a tumoral cell recognizer, and on the other hand an anticancer agent(cisplatin). The recognizer is expected to link to some membrane receptors which are overexpressed in tumoral cells (EGFR) and the antitumoral is therefore endocyted by the cell and exerts its activity modifying the tyrosine-kinase chain.
The main characteristic is the improvement of the specificity issue on drug delivery due to the specific recognition of EGFR by the EGF, which eventually could lead to an increase in the local concentration of the drug in the area of the tumoral cells. This synergistic effect has been tested in vitro and in vivo, in mice models. H460 cell lines have been use as human lung cell. From the results obtained, it can be said that the microparticles (DDS) conducted a good survival on the animals in comparison with the free drug. In addition a lower degree of metastases were also appeared. Therefore, the results of this study clearly indicate that there is a great potential of cisplatin-EGF-microparticles to be use in human lung carcinoma.

The specific advantages of the system are as follows:

#The increase of effective drug concentration in the tumour cells area.
#A significant reduction in the drug needed to inject into the patient.
#The reduction of the possible adverse effects acuteness due to the effect of the drug in other tissues.


Maria Angeles Serrano, (Research ViceChancellor)
Tel.: +34923294430
Fax: +34923294502
Numero di registrazione: 183512 / Ultimo aggiornamento: 2016-06-07
Fonte d'informazione: SESAM